CA Patent

CA3255688A1 — Treatment of low-grade glioma with mirdametinib

Assigned to St Jude Childrens Research Hospital · Expires 2023-09-21 · 3y expired

What this patent protects

This disclosure relates to a method of treating a patient (a human patient, for example) with inferior quality gilomata by administering mirdamethinb or a pharmaceutically acceptable salt orally to the patient.

USPTO Abstract

This disclosure relates to a method of treating a patient (a human patient, for example) with inferior quality gilomata by administering mirdamethinb or a pharmaceutically acceptable salt orally to the patient.

Drugs covered by this patent

Patent Metadata

Patent number
CA3255688A1
Jurisdiction
CA
Classification
—
Expires
2023-09-21
Drug substance claim
No
Drug product claim
No
Assignee
St Jude Childrens Research Hospital
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.